ResMed Inc. Form 8-K Summary
Business Context and Reporting Period
ResMed Inc. (NYSE: RMD), a Delaware corporation, filed this Current Report on Form 8-K on August 31, 2026. The filing details a significant corporate action regarding the repurchase of the company's common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Accelerated Share Repurchase (ASR) Agreement.
- Counterparty: Citibank, N.A.
- Total Commitment: $450.0 million.
- Funding Source: Proceeds from the sale of the MatrixCare business and cash on hand.
- Authorization: Conducted under a board-approved authorization for 20,000,000 shares (approved February 2014).
- Payment Date: $450.0 million to be paid on September 3, 2026.
- Initial Share Delivery: Expected on September 3, 2026, equal to 80% of the commitment value divided by the closing stock price on September 2, 2026.
- Final Settlement: Scheduled for December 2026, based on the average daily volume-weighted average price (VWAP) during the term, less a discount.
Material Changes and Prior Period Comparison
This filing represents a new material event and does not report comparative financial performance metrics (revenue, profit, margins) against a prior period. The transaction was explicitly contemplated in the guidance issued for fiscal year 2027 during the Q4 FY26 earnings call on August 6, 2026.
Guidance, Outlook, and Risks
The ASR transaction aligns with the company's previously issued fiscal year 2027 guidance. The final number of shares repurchased is subject to market volatility and the terms of the ASR Agreement. At settlement, Citibank may deliver additional shares, or the Company may be required to deliver shares or make a cash payment to Citibank, depending on the average stock price during the term.
Key Facts for Investor Verification
- Verify the closing stock price on September 2, 2026, to estimate the initial share count delivered.
- Monitor the final settlement in December 2026 to determine the total number of shares repurchased and the effective average price.
- Confirm the status of the MatrixCare business sale proceeds as a funding source for the $450.0 million payment.
- Review the remaining balance of the 20,000,000 share repurchase authorization post-transaction.